Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission: A pilot study
- 31 December 1990
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 14 (11-12) , 967-973
- https://doi.org/10.1016/0145-2126(90)90109-m
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- An Acquired Chemotactic Defect in Neutrophils from Patients Receiving Interleukin-2 ImmunotherapyNew England Journal of Medicine, 1990
- IL-2 and myelopoiesis: IL-2 induces blast cell proliferation in some cases of acute myeloid leukaemiaBritish Journal of Haematology, 1989
- Interleukin 2 and its receptor: Structure, function and therapeutic potentialBlood Reviews, 1987
- Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patientsBlood, 1987
- Induction of NK cell activity against fresh human leukemia in culture with interleukin 2.The Journal of Immunology, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIALThe Lancet, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- ACTIVE IMMUNOTHERAPY FOR ACUTE LYMPHOBLASTIC LEUKÆMIAThe Lancet, 1969